Effect of GnRH Agonist in FET
ConditionGnRH Agonist
Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexFemale
Age20-39
SponsorAssiut University
About this trial
To evaluate the impact of single dose GnRH agonist administration as luteal phase support on pregnancy outcomes in frozen ICSI cycle
Eligibility criteria
Qualifiers
1. Age 20-39 years 2. Undergoing HRT-FET cycle 3. ≥1 good quality embryo available , Gardner ≥3BB 4. Endometrial thickness ≥7mm on day of progesterone start 5. BMI 18-35 kg/m² 6. First or second FET cycle 7. Written informed consent
Disqualifiers
1. History of recurrent implantation failure ≥3 failed embryo transfers 2. Severe endometriosis Stage III-IV by ASRM 3. Uterine anomalies, submucous fibroid, or severe adenomyosis distorting cavity 4. History of recurrent pregnancy loss ≥2 consecutive 5. Contraindication or hypersensitivity to GnRH agonist 6. PGT-A cycles 7. Donor oocyte cycles
Trial design
Treatments tested in this trial
- GnRH agonist
Treatment groups
122 Participants
are divided into 2 treatment groupsSponsors and collaborators
Assiut University
Lead sponsor
Woman's Health University Hospital, Egypt
Collaborator
Source ClinicalTrials.gov